{"name":"ISU Abxis Co., Ltd.","slug":"isu-abxis-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Abcertin","genericName":"Abcertin","slug":"abcertin","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Cerezyme®","genericName":"Cerezyme®","slug":"cerezyme","indication":"Gaucher disease type 1 (non-neuronopathic form)","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Fabagal® (Agalsidase beta)","genericName":"Fabagal® (Agalsidase beta)","slug":"fabagal-agalsidase-beta","indication":"Fabry disease (α-galactosidase A deficiency)","status":"phase_3"}]}],"pipeline":[{"name":"Abcertin","genericName":"Abcertin","slug":"abcertin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cerezyme®","genericName":"Cerezyme®","slug":"cerezyme","phase":"marketed","mechanism":"Cerezyme is an enzyme replacement therapy that provides the missing glucocerebrosidase enzyme to break down glucocerebroside in patients with Gaucher disease.","indications":["Gaucher disease type 1 (non-neuronopathic form)","Gaucher disease type 3 (chronic neuronopathic form)"],"catalyst":""},{"name":"Fabagal® (Agalsidase beta)","genericName":"Fabagal® (Agalsidase beta)","slug":"fabagal-agalsidase-beta","phase":"phase_3","mechanism":"Agalsidase beta is a recombinant human enzyme that replaces deficient α-galactosidase A, breaking down accumulated globotriaosylceramide (Gb3) in cells.","indications":["Fabry disease (α-galactosidase A deficiency)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNanRobzAyR0tPeS1qWEM0SjBkaUh5NmlmeWx5dVUwYXNFTU0zM25VT1ZVMWRGc0tnc3liQ2xIdmIxZ0dTTFV5VlJpUXBPZVJiRGEzT1d6NHdPMUVWWGtua2M1WlMtZGJnNi03TWpCa0VrRFRXTEQxUVVDRzBOSjVjUHV4djNrVG02cFZHSzc4UE5GWXVPamZEWmlDdkxRaW1MS3lLdmNjcUZOZThVOG5ZUXpod0FHMFRFdWltclBhUS1lUUMtZ0hUZkprMFRQbXJxYkluZ2tDWFZrY3pTYWZMVTV2dVBuUnhaT3JHTWpiNHJBei1ZYURmOWxBc0Q1OVhacmFHQ1ZNMEdwWFEtWi1YVmtNR1NUODVMQlBLdkhIR1BCaWxFWExzTVN3?oc=5","date":"2026-03-31","type":"pipeline","source":"Barchart.com","summary":"Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart.com","headline":"Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPMXdJSkhETEFsX2xWU2hjTHhSdmxsdGw0dXJUUjlVbF9oZ1lKcnNVLUd2OVhVRFVFWTRsaU9lY0tUM2QzWkNhV1RpNGlEd3pCN011U0hTQUhReE1tdU1BaEktZDRVVHZvUll0ak4xU0J6SUFSWFpZZ3RGTURoSThIdTVDV25VaGxsNGtSTmtJd1l6bjBES1doOThtb2drRmtJVk5CT0VzejhkRlU?oc=5","date":"2026-02-10","type":"pipeline","source":"BioWorld News","summary":"AI meets antibody design: Galux draws $29M series B for drug R&D - BioWorld News","headline":"AI meets antibody design: Galux draws $29M series B for drug R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1YcjZrOVJJQXVCMUhMUWhOUDVaSjNzYkxwVERDcnplYWN1Ui03QmoxOHlzT0pEcEJxcUlNNEVqZEFuRS12Nzh6Z1B4WkpiM2QzbXMycmdEUkRZaUhqcmNFV0RXMENTM0ZuSWdlS2pKRjJtc09lOXgyQ0k1WG8?oc=5","date":"2025-12-02","type":"pipeline","source":"Fact.MR","summary":"Lysosomal Storage Disease Treatment Market | Global Market Analysis Report - 2035 - Fact.MR","headline":"Lysosomal Storage Disease Treatment Market | Global Market Analysis Report - 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE55RGJHeGpLNzVfYzQ2aXVmRnVKRS1PcGpSd2FOUHAtVlo3akdDR0xPeVQ1b0xFZ2hyOVZBUnpscm5oS0hqMnh3UHZqUm85U05KaFpJUzRUQWJZejJWdXo3RjhnTTluR01tX0JEeGZn0gFyQVVfeXFMUDdtaDJxOUVhanZVLXZWMU11Q0VZRmw5em5RaDI3MlFjdDcxM2NIaVdDdHJxWEk0NE5weGRCUk1TcmlfTzBvQU45T044cnVDNUlYUmhETkF0S0s2YXBGdnQyOTdGRGN2TjFyNkRPa2tZVFpR?oc=5","date":"2025-05-16","type":"trial","source":"koreabiomed.com","summary":"GC Biopharma and Hanmi kick off global trial for once-monthly Fabry drug - koreabiomed.com","headline":"GC Biopharma and Hanmi kick off global trial for once-monthly Fabry drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOUVVGN0pqSktYbDVqOE12LWFaV0gwY1dBaW4welk1X3FwakJsTnM2ZEZwLVZJOWl0RUFlWEVjTzZEaEpIcmJyR215U1dFaVJlaGM1cDV2eU1lNGRYaS1adUlUdjF0MjhVSUlab0IxVlg2SUdmMkVXRnV0enlPTTI0YmtVUzZvR3hseHIwLWtRejd3VXl5eXZEejZnQU02TWFCLXByT21vMTJxdGNqY2hDMWFreDFYVnVHbnVSWFVlNkxya3FaN2VIczMyMFNDSktFakNSMkRtWFZpUVRNNVh0cGt5N0ZGVEo0NU1jVjFhNzNWbHNOWENlQ3E4S0kyaDVZaWhTM3d3Z0RKdlBYLUd0dWg1ajd3a1pnU2pnc2hCSVNfREY4RXB0dVJjYUpSY3I3cWhxUDdfZw?oc=5","date":"2024-10-28","type":"trial","source":"GlobeNewswire","summary":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire","headline":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQTnFBZFpYM1JaaTF4UGtyZmlHQm1rSjVlSWgzOHNob1V6M1hzTGNha0hCMlBRZmdqLWxOZmI5MEJ5Z09HS1l0M1ktajZ1enNzYzBxYmtKMFlQajFBcTRuMVlBM3JFVFZ5My14Nm5vaXFpRWktTW5MSDlkZkRKM05mOExFX0JkVFhGUWZNejF3eXYtSi1Ga0Jr?oc=5","date":"2024-07-17","type":"pipeline","source":"BioWorld News","summary":"Sotio, Biocytogen link up in $325M ADC discovery pact - BioWorld News","headline":"Sotio, Biocytogen link up in $325M ADC discovery pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBmRGtiTkVVN09vdmFrWmhWcnprTDJLSWRadEdvY09QUDhSd01fYTBaUE9QSmF1Q1Q5aEtfTTVZTVBSeGVXTjl2WVVGOXlYRnZYMWw1bDJLQmxrX1NaS3ZUeVc1Wm1SbkRHbnlUaFBR?oc=5","date":"2023-12-08","type":"patent","source":"KED Global","summary":"ISU Abxis gets patent for Alzheimer drug candidate in Taiwan - KED Global","headline":"ISU Abxis gets patent for Alzheimer drug candidate in Taiwan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9TOTZVUXNiTkRNS1dXR2RhWl8tenM3ejlQUnZYbHd4bU1wVTVvVS16cGpzMVhCWmNwWURPTll5QkFtWWhCNFVpQ2w4U2ZMUll5dGQ4dDRGbGExZmRPb2x1UUhpcTNFaTVQOG8xWUFxdUJTNU0?oc=5","date":"2023-10-23","type":"pipeline","source":"Straits Research","summary":"Fabry Disease Treatment Market Size, Share And Growth | 2033 - Straits Research","headline":"Fabry Disease Treatment Market Size, Share And Growth | 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPMGZSSThMRmdVUHRzRWlpNmd2blJFd3BFeC1ZUUMtdUJQU3VGMFFUT1lUQi01a0RJNHlhRVZieE00NHVaVW9WRmc3TkN1QmxlY2gzSzVOUDlUYTZ2LUpYeG1LOGphSDBad2p1WllEaS1ESmlXc1Q4TURHZmhOWk9IeVRBbmpsYTZpMTFqWWRXSQ?oc=5","date":"2021-07-19","type":"pipeline","source":"openPR.com","summary":"Fabry Disease Treatment (2021-2030) | Potential growth, - openPR.com","headline":"Fabry Disease Treatment (2021-2030) | Potential growth,","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}